Outcome of allografting for AML-CR2 is equivalent across BSBMT and EBMT and is associated with encouraging OS and DFS across all age groups by Byrne, Jenny et al.
1 
 
Outcome of Allografting for AML-CR2 is equivalent across the 
BSBMT and EBMT and is associated with encouraging OS and DFS 
across all age groups. 
Jenny Byrne1,2, Rachel Pearce2, Julia Perry2, C Crawley3.2, Graham Jackson4,2 
 
Affiliations: 
1Nottingham University Hospitals Trust, Nottingham, UK 
2British Society for Blood and Marrow Transplantation, Guys and St Thomas Hospital, 
London, UK 
3 Addenbrookes Hospital Trust, Cambridge, UK 
4 Newcastle Royal Infirmary Trust, Newcastle, UK 
 
Corresponding author: 
Dr Jenny Byrne 
Department of Haematology 
Nottingham University Hospitals Trust 
Hucknall Road, Nottingham NG5 1PB 
 
None of the authors have any Conflicts of Interest to declare. 
 
Running Title: Outcomes of allografting for AML-CR2… 
2 
 
  
Allogeneic HSCT is the most effective anti-leukaemic therapy for AML. However, due to the 
significant risks of transplant-related mortality (TRM) from infection, regimen-related toxicities and 
graft versus host disease (GVHD), not all patients receive transplants in CR1. Currently this decision 
depends on risk stratification, balancing the risks of relapse versus TRM. In general, allogeneic 
transplantation is reserved for intermediate or poor risk patients in CR1, but not good risk patients 
who have a lower chance of relapse and a high chance of salvage1,2.  Following relapse, AML has a 
poor outlook3. The only curative approach is with an allogeneic transplant following re-induction 
chemotherapy, where superior outcomes have been confirmed as compared to those not 
transplanted4,5.  It is often perceived that allografts for AML-CR2 have inferior outcomes as 
compared to CR1 transplants, but there is limited published data for those allografted in CR2 since 
most studies report data for CR1 and CR2 patients combined.  
We analysed the outcomes of 534 UK and 3070 AML-CR2 patients reported to the EBMT, from 2006-
11. There was a 50% increase in the number of AML-CR2 allografts performed during this time-
period in both BSBMT (70 to 104) and EBMT (420 to 623) cohorts. RIC conditioning regimens 
exceeded myeloablative regimens, accounting for 55% and 66% of transplants done by the BSBMT 
and the whole cohort. Furthermore, 19% of UK allografts for AML-CR2 and 16% of the EBMT cases 
were in patients aged > 60 years. The proportion of paediatric cases was similar (14% and 15%) in 
the two cohorts. Greater than 60-75% of the allografts were performed using an unrelated donor 
and the source of stem cells was PBSC in > 70% of cases, with 10% or fewer being from cord blood. 
Although the length of CR1 was largely unknown, the median time from AML diagnosis to transplant 
was 18-19 months in both groups suggesting an average CR1 duration of 6-12 months. 
The median follow up for the BSBMT cohort was 4.75 years and 3.3 years for the EBMT. Overall 
survival (OS) at 3 and 5 years for the BSBMT group was 49% and 44% and for the EBMT was 53% and 
48% respectively (p=ns). Similarly, there was no difference between the BSBMT and the EBMT 
3 
 
cohorts in LFS rates, TRM rates, or relapse rates at 1, 3 or 5 years. Most relapses occurred early with 
23% and 21% at 1 year in the BSBMT and EBMT groups rising to 29% and 30% at 3 years. The D100 
TRM rates were low at 9% and 10% for the UK and EBMT cohorts, rising to 29% and 27% at 5 years. 
The incidence of both acute (50% versus 48%) and chronic GVHD (49% versus 35%) were similar 
between the two groups. 
Multivariate analysis of factors influencing OS revealed age and time from diagnosis to transplant to 
be significant. The impact of age was striking with paediatric patients aged < 18 years having the 
best OS of 58% at 3 years as compared to 52% for those aged 18-60 years and 45% for those aged > 
60 years. Relapse was significantly higher in those receiving RIC versus MAC conditioning, who had 
no acute GVHD and a shorter time from diagnosis to transplant. Similarly, LFS was influenced by time 
from diagnosis to transplant and type of conditioning, whilst age, source of stem cells, presence of 
acute GVHD and time from diagnosis to transplant influenced TRM (Figure). 
Allogeneic transplants for AML-CR2 represent an important part of any allograft program. Ever since 
cytogenetic risk groups were characterised, most patients with monosomal/adverse risk karyotypes 
have been transplanted in CR1 and thus those allografted in CR2 represent a distinct group, 
comprising patients with intermediate/good risk cytogenetic profiles. In this study, cytogenetic data 
was incomplete and so could not be analysed for its impact on outcomes. More recently, AML risk 
stratification has included molecular analysis, but at the time of this study few patients had 
molecular profiles recorded. 
The factors impacting OS, relapse and TRM were all expected. The best results were observed in 
patients aged < 18 years who had a 3 year OS of 58%. The negative effect of increasing age on OS 
and TRM has long been recognised and there was a clear inferior survival for those aged > 60 years 
compared to those aged 18-60 years6,7. Furthermore the higher TRM rates and reduced OS seen with 
the use peripheral blood or cord blood was expected given the known increased risk of GVHD 
following PBSC transplants8 and the increased risk of graft failure and NRM following cord blood 
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transplantation9. Similarly, the increased relapse risk in patients undergoing RIC transplants, those 
with shorter CR1 duration and no acute GVHD are well known, as is the increased TRM in patients 
developing acute GVHD. It is encouraging that no major differences were observed between the 
BSBMT and EBMT cohorts in this benchmarking study confirming that outcomes are comparable 
across Europe for AML-CR2 patients. 
The increasing number of AML-CR2 allografts during this time-period may reflect the increasing use 
of risk stratification algorithms in AML, which select out only high risk patients for allografting in 
CR1. For such strategies to be justifiable it is important that transplant outcomes in CR-2 is 
comparable to that in CR1. It is encouraging that the 5 year OS of 44% and 48% in the BSBMT and 
EBMT cohorts is comparable with other studies which have reported 50% and 42% 5 year OS for 
AML-CR25,10,. In addition, these outcomes are reasonable compared to those reported for adult 
patients in CR1, where 3 year OS of 51%  and 5 year OS of 54% have been reported11, thus 
supporting the concept of reserving allografts for poor risk patients in CR1.  
Another reason for the increased CR2 allografts may be that more patients are eligible due to more 
successful re-induction regimens, or the introduction of RIC regimens, which enable older and less fit 
patients to undergo transplantation. Indeed, 16% of our patients were aged > 60 years and their OS 
was 45% at 3 years, which questions previous studies that have suggested that allogeneic 
transplantation in patients > 60 years be limited to those in CR112. The superior results observed for 
older patients in CR2 may reflect better patient selection and lower HCT-CI scores, although this 
cannot be proven as comorbidity scores were unavailable. 
In summary, this large registry study confirms acceptable outcomes for AML-CR2 allografts in all age 
groups and supports risk stratification and reservation of allo-transplantation in CR1 for high risk 
patients. It is likely that risk stratification models will continue to evolve as new molecular prognostic 
data and MRD information is included and thus patient selection will be further refined. 
5 
 
 
 
References 
1. Cornelissen J, Gratwohl A, Schlenk R, Sierra J, Bornhauser M, Juliusson G et al. The 
European LeukemiaNet AML Working Party consensus statement on allogeneic 
HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat 
Rev Clin Oncol 2012; 9 : 579-590 
2. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T et al. 
Diagnosis and management of AML in adults: 2017 ELN recommendations from an 
international expert panel. Blood 2017; 129 :424-447 
3. Forman SJ and Rowe JM. The myth of the second remission of acute leukaemia in 
the adult. Blood 2013; 121:1077-1082 
4. Gale R, Horovitz M, Rees JK, Gray RG, Oken M, Estey EY et al. Chemotherapy versus 
transplantation for acute myelogenous leukemia in second remission. Leukemia 
1996; 10: 13-19 
5. Burnett AK, Goldstone A, Hills RK, Milligan D, Prentice A, Yin J et al. Curability of 
patients with acute myeloid leukaemia who did not undergo transplantation in first 
remission. J Clin Onc 2013; 31: 1293-1301 
6. Michelis FV, Atenafu EG, Gupta V, Kim D, Kuruvilla J, Lambie A et al. Duration of first 
remission, haemopoietic cell transplantation-specific comorbidity index and patient 
age predict survival of patients with AML transplanted in second CR. Bone Marrow 
transplant 2013; 48: 1450-1455 
6 
 
7. Michelis FV, Messner HA, Atenafu EG, McGillis L, Lambie A, Uhm J et al. Patient age, 
remission status and HCT-CI in a combined score are prognostic for patients with 
AML undergoing allogeneic hematopoietic cell transplantation in CR1 and CR2. 
Bone Marrow Transplant 2015; 50: 1405-1410 
8. Holtick U, Albrecht M, Chemnitz JM, Theurich S, Skoetz N, Scheid C et al. Bone 
marrow versus peripheral blood allogeneic haematopoietic stem cell 
transplantation for haematological malignancies in adults (Review) Cochrane 
Database of System Rev 2014 Apr 20;(4):CD010189 
9. Eapen M, Rocha V, Sanz G, Scaradavou A, Zhang MJ, Arcese W et al. Effect of graft 
source on unrelated donor haemopoietic stem-cell transplantation in adults with 
acute leukaemia: a retrospective analysis. Lancet Oncol 2010; 11: 653-70 
10. Weisdorf DJ, Millar HR, Horowitz MM, Hyare PS, Champlin R, Ho V et al. Allogeneic 
transplantation for advanced acute myeloid leukemia: the value of complete 
remission. Cancer 2017; 123: 2025-2032 
11. Koreth J, Schlenk R, Kopecky K, Honda S, Sierra J, Djulbegovic B et al. Allogeneic 
stem cell transplantation for acute myeloid leukemia in first complete remission: a 
systematic review and meta-analysis of prospective clinical trials. JAMA 2009; 301: 
2349-2361 
12. Michelis FV, Messner HA, Atenafu EG, Kim DD, Kuruvilla J, Lipton JH et al. Benefit of 
allogeneic transplantation in patients age > 60 years with acute myeloid leukaemia 
is limited to those in first complete remission at time of transplant. Biol BMT 2014; 
20; 474-479 
 
 
7 
 
Figure Legends 
 
Figure 1 
Survival curves  
a) Overall survival of AML-CR2 allografts, BSBMT versus EBMT 
b) Leukaemia-free survival of AML-CR2 allografts, BSBMT versus EBMT 
c) Overall survival of whole group by age (< 18 yrs, 18-60 years and > 60 years) 
d) Leukaemia free survival of whole group by time from diagnosis to transplant (< 18 months 
compared to > 18 months) 
e) Non-relapse mortality of whole group by stem cell source (bone marrow versus PBSC versus cord 
blood) 
f) Relapse rate of whole group by type of conditioning (RIC versus MAC) 
